Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
April 03, 2023 09:00 ET
|
Anika Therapeutics Inc.
Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing Anika reaches agreement to distribute the Marrow Cellution™ Bone Marrow...
Anika Files Preliminary Proxy Statement
March 27, 2023 08:55 ET
|
Anika Therapeutics Inc.
BEDFORD, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today...
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
March 15, 2023 16:01 ET
|
Anika Therapeutics Inc.
BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management...
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
March 08, 2023 10:00 ET
|
Anika Therapeutics Inc.
Recently Commenced Full Market Release of X-Twist™ Fixation System, a Cornerstone Product in Anika’s Sports Medicine Portfolio RevoMotion™ Reverse Shoulder Arthroplasty System Now in Limited Market...
Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results
March 06, 2023 16:05 ET
|
Anika Therapeutics Inc.
Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6% Completed First Surgeries and Initiated Limited Market Release of New RevoMotion™ Reverse Shoulder Arthroplasty...
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
February 28, 2023 09:00 ET
|
Anika Therapeutics Inc.
BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will...
Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023
February 21, 2023 10:30 ET
|
Anika Therapeutics Inc.
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company...
Anika Issues Statement
February 21, 2023 10:00 ET
|
Anika Therapeutics Inc.
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today issued the following statement...
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
February 13, 2023 08:30 ET
|
Anika Therapeutics Inc.
RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market RevoMotion offers the industry’s smallest...
Anika Reports Third Quarter Fiscal 2022 Financial Results
November 08, 2022 16:05 ET
|
Anika Therapeutics Inc.
Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone ...